EP-262
N/A
Report date: 2024/11/19 14:54:12
NMEFirst In Class
Base Information
Drug NameEP-262
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[6]
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEscient Pharmaceuticals Inc
China Registration ClassN/A
Develop Information
Active CompaniesIncyte CorpEscient Pharmaceuticals Inc
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A